Last reviewed · How we verify
PAZOPANIB
Pazopanib inhibits multiple tyrosine kinases, blocking angiogenesis and tumor growth.
At a glance
| Generic name | PAZOPANIB |
|---|---|
| Drug class | Kinase Inhibitor [EPC] |
| Target | VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-ɑ, PDGFR-β, FGFR-1, FGFR-3, Kit, Itk, Lck, c-Fms |
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 2009 |
Mechanism of action
Pazopanib works by inhibiting several tyrosine kinases that are involved in the growth and development of blood vessels and tumors. By blocking these receptors, it prevents the formation of new blood vessels that feed tumors and slows down tumor growth.
Approved indications
Boxed warnings
- WARNING: HEPATOTOXICITY Severe and fatal hepatotoxicity has been observed in clinical trials. Monitor hepatic function and interrupt, reduce, or discontinue dosing as recommended [see Warnings and Precautions ( 5.1 )] . WARNING: HEPATOTOXICITY See full prescribing information for complete boxed warning. Severe and fatal hepatotoxicity has been observed in clinical trials. Monitor hepatic function and interrupt, reduce, or discontinue dosing as recommended. ( 5.1 )
Common side effects
- Diarrhea
- Hypertension
- Hair color changes
- Nausea
- Anorexia
- Vomiting
- Fatigue
- Asthenia
- Abdominal pain
- Headache
Key clinical trials
- Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery (PHASE2, PHASE3)
- Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors (PHASE1)
- Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery (PHASE3)
- Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors (PHASE2)
- Drug Screening Using Novel IMD in Renal Cell Carcinoma (PHASE1)
- Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz) (PHASE2, PHASE3)
- A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas (PHASE1)
- Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PAZOPANIB CI brief — competitive landscape report
- PAZOPANIB updates RSS · CI watch RSS